Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7.

As a transcription factor, the Wilms' tumor 1 (WT1) gene plays an important role in leukemogenesis. The impact of WT1 gene mutations has been reported in acute myeloid leukemia (AML). However, the number of available studies on the spatial configuration changes following WT1 mutation is limited. In this study, we sequenced the mutation in exon 7 of the WT1 gene in 60 children with newly diagnosed AML and the spatial configuration of WT1 with frameshift mutations in exon 7 was evaluated using the software for homology modeling and optimization of molecular dynamics. Three cases with frameshift mutations in exon 7 were identified (3/60; mutation rate, 5%). One case had a mutation that had been previously described, whereas the remaining two mutations were first described in our study. Of the three cases, one case presented with antecedent myelodysplastic syndrome (MDS) and the remaining two cases exhibited primary resistance to induction chemotherapy. The spatial configuration analysis demonstrated that the three mutations affected the spatial structure of exon 7 and even affected exon 8 compared to its wild-type. This study demonstrated that the frameshift mutation in exon 7 of the WT1 gene is a poor prognostic factor for children with AML, partly through the spatial configuration changes following frameshift mutations of WT1, which highlights the structure-based function analysis and may facilitate the elucidation of the pathogenesis underlying WT1 gene mutations.

[1]  Julia Kuhn,et al.  WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Raimondi,et al.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.

[3]  Guido Marcucci,et al.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Blood.

[4]  Claude Pouchan,et al.  The VCI-P code: an iterative variation–perturbation scheme for efficient computations of anharmonic vibrational levels and IR intensities of polyatomic molecules , 2010 .

[5]  P. Zielenkiewicz,et al.  Why similar protein sequences encode similar three-dimensional structures? , 2010 .

[6]  R. Arceci WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system , 2010 .

[7]  S. Raimondi,et al.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.

[8]  R. Pieters,et al.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.

[9]  L. Bullinger,et al.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.

[10]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[11]  H. Dyson,et al.  Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. , 2007, Journal of molecular biology.

[12]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[13]  S. Ariyaratana,et al.  The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis , 2007, Expert Reviews in Molecular Medicine.

[14]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[15]  [Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[16]  I. Touw,et al.  Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation , 2005, Oncogene.

[17]  K. Pritchard-Jones,et al.  Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. , 1998, Blood.

[18]  U. Maurer,et al.  Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. , 1997, Blood.

[19]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[20]  M. Little,et al.  A clinical overview of WT1 gene mutations , 1997, Human mutation.

[21]  T. Kyo,et al.  Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. , 1996, Blood.

[22]  K. Pritchard-Jones,et al.  Mutations in the Wilms' tumor gene WT1 in leukemias. , 1996, Blood.

[23]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[24]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.